Posaconazole followed by posaconazole
Phase 2Small molecule
Posaconazole followed by posaconazole is one of 7 small molecule programs targeting Mucormycosis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Mucormycosis
#DrugCompanyPhaseTrials
1Abelcet
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Noxafil
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Exjade
NovartisPhase 2
Liposomal Lurtotecan
GileadPhase 2
Inhaled Amphotericin
PPost Graduate Institute of Medical Education and Research, Chandigarh
Phase 2
Isavuconazole
AstellasPreclinical
Posaconazole followed by posaconazole
PPost Graduate Institute of Medical Education and Research, Chandigarh
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Mucormycosis1 trial
Amphotericin Versus Posaconazole for Pulmonary Mucormycosis
Recruiting·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 2·NCT05468372·50 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details